Angiogenesis Foundation
News & MediaThe Angiogenesis Foundation Earns Charity Navigator’s Esteemed 4-Star Rating
The Angiogenesis Foundation announced today it has earned the esteemed 4-star rating from Charity Navigator – America’s premier independent charity evaluator. The honor is awarded to an elite group of nonprofits meeting the highest criteria possible for financial...
Doctor and Rock Star Bring Mission of Health Equity to Vatican Via Foods that Fight Disease
CAMBRIDGE, Mass., May 11, 2016/PRNewswire/ -- Dr. William Li and musician and activist The Edge of U2, both board members of the non-profit Angiogenesis Foundation, delivered a speech and a performance respectively to more than 200 world leading medical scientists,...
FDA Approves Afinitor for Gastrointestinal, Lung Neuroendocrine Tumors
The FDA has approved Afinitor (everolimus) for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal (GI) or lung neuroendocrine tumors (NET), based on findings from the phase 3 RADIANT-4...
Ultimate Food Fight: The Angiogenesis Foundation’s Declaration of War on Cancer and Other Non-Communicable Diseases Using Diet
Inaugural World Summit on Food and Health in Paris Convened Innovative Thinkers from Science, Medicine, Culinary, Technology, and Aerospace Fields to Address Global Health Crisis CAMBRIDGE, Mass., Feb. 12, 2016 /PRNewswire-USNewswire/ -- The nonprofit Angiogenesis...
Anti-VEGF Agent Ramucirumab Approved to Help Treat mCRC
The U. S. Food and Drug Administration approved ramucirumab for use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line bevacizumab-, oxaliplatin- and...
Dr. William Li Delivers Keynote Address at the American Professional Wound Care Association National Clinical Conference
Dr. William Li, President and Medical Director of the Angiogenesis Foundation, gave the keynote address at the 2015 American Professional Wound Care Association (APWCA) National Clinical Conference, in Philadelphia, PA. The keynote, “Essential Imaging in Limb...
People with Diabetes Have More Options: FDA Approves Anti-VEGF Agent Aflibercept for Diabetic Retinopathy
The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema. Diabetic retinopathy (DR) is the most common diabetic eye disease and is a leading cause of...
FDA Approves Anti-VEGF Agent Lenvatinib for Progressive Differentiated Thyroid Cancer
The U.S. Food and Drug Administration (FDA) has approved lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease). Lenvima...
Antiangiogenic Agent Bevacizumab Gets EU Recommendation for Treating Cervical Cancer
The European Union's (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of bevacizumab (Avastin) in combination with standard chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan in patients who cannot receive platinum...
Anti-VEGF Agent Aflibercept Approved for Treatment of Macular Edema Secondary to Retinal Vein Occlusion in the European Union
Anti-VEGF agent aflibercept (EYLEA®) has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Retinal Vein Occlusion (RVO). The new indication includes Macular Edema following Branch Retinal Vein Occlusion...
Big news for people with diabetes: Anti-VEGF agent ranibizumab approved to treat diabetic retinopathy to prevent vision loss
The U.S. Food and Drug Administration today expanded the approved use for ranibizumab injection 0.3 mg (Lucentis) to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME). Diabetic retinopathy is the most common diabetic eye disease and is a...
Anti-VEGF Agent Lenvatinib Improves Progression Free Survival in Patients with Radioiodine-Refractory Thyroid Cancer
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, was associated with significant improvements in progression-free...
President of the Angiogenesis Foundation Will Serve as Co-Chair for iSPIES
President and Medical Director of the Angiogenesis Foundation Dr. William Li will serve as co-chair of the Summit for Perfusion Imaging and Excellence in Surgery (iSPIES). The summit strives to help clinicians better understand the role of fluorescence imaging in the...
Benefits of Antiangiogenesis Could Expand to Tuberculosis Patients
Use of the same antiangiogenesis drugs that have improved treatment of some cancers could also help surmount persistent difficulties in treating tuberculosis (TB). In their PNAS Early Edition report, investigators from Massachusetts General Hospital (MGH) and the...
Questionable Findings on the Benefits of Combining Bevacizumab with FOLFOXIRI for Metastatic Colorectal Cancer
To the Editor: In their article on the Triplet plus Bevacizumab (TRIBE) study, Loupakis et al. (Oct. 23 issue) conclude that chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improved the outcome of patients with...
Combining Antiangiogenic Agent Bevacizumab with Chemotherapy Significantly Improved Overall and Progression-Free Survival in Advanced Cervical Cancer Patients
GOG 240 was a practice-changing randomized phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall and progression-free survival, and the proportion of patients achieving an overall objective...
The Angiogenesis Foundation in Fitness Magazine on Cancer Prevention
Fitness Magazine, a monthly publication circulated to approximately 1.5 million people, has interviewed President and Medical Director of The Angiogenesis Foundation Doctor William Li for an article in its February issue, “Cancer Proof Your Life.” Dr. Li shares a...
Low-Frequency Ultrasound Shown to Significantly Improve Healing of Venous Leg Ulcers
Chronic leg ulcers that heal poorly can become infected, lead to limb amputation, and severely compromise quality of life. More than 80% of all chronic leg ulcers are venous leg ulcers1 (VLUs) caused by abnormal back flow in the veins of the lower leg. The increased...
Anti-VEGF Agent Aflibercept Recommended in the European Union for Approval for Treatment of Macular Edema due to Branch and Central Retinal Vein Occlusion
Aflibercept (EYLEA®) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to macular edema secondary to branch or central retinal vein occlusion (BRVO/CRVO). The...
The Angiogenesis Foundation Convenes the Canadian National Multistakeholder Expert Summit for Diabetic Macular Edema
Diabetes is the leading cause of blindness among adults aged 20-74. Patients with type 1 or type 2 diabetes are at risk for developing diabetic retinopathy, a debilitating eye disease, which can lead to the more severe condition of diabetic macular edema (DME). The...
Breakthrough Treatment for Chronic Wounds Gives Patients New Hope
For someone with diabetes, a stubbed toe, trivial scrape, or minor cut can rapidly become serious. This condition impairs the body’s healing ability, so a small wound can become life threatening. It is estimated that chronic wounds affect as many as 1 – 2% of people...
Antiangiogenic Agent Ramucirumab Gets FDA Approval for Treating Non-Small Cell Lung Cancer
The US Food and Drug Administration (FDA) expanded the indication of ramucirumab (Cyramza, Eli Lilly) to include the treatment of metastatic non-small cell lung cancer (NSCLC). Ramucirumab is a fully human monoclonal antibody that was developed for the treatment of...
Anti-VEGF Agent Ranibizumab Gets FDA Breakthrough Therapy Designation for Diabetic Retinopathy
The US Food and Drug Administration (FDA) has granted Lucentis (ranibizumab), a vascular endothelial growth factor (VEGF) inhibitor, its Breakthrough Therapy (BT) designation for the treatment of diabetic retinopathy. Diabetic retinopathy is a vision-threatening...
Anti-VEGF Agent Aflibercept Approved in Canada for Treating Diabetic Macular Edema (DME)
Health Canada recently approved anti-VEGF agent alibercept (Eylea) for the treatment of diabetic macular edema (DME). Eylea is also approved in Canada for the treatment of visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) and...